GLP-1 Side Effects: Hypoglycemia, Nausea, Constipation, and Sulfur Burps Explained

What Is the True Hypoglycemia Risk on GLP-1 Medications?

GLP-1 receptor agonists carry a low intrinsic hypoglycemia risk in patients who are not also taking insulin or a sulfonylurea. The glucose-dependent mechanism is the reason: these drugs stimulate insulin release only when blood glucose is elevated, so insulin secretion drops off as glucose approaches normal range. Standalone therapy with semaglutide or tirzepatide does not reliably push glucose below 70 mg/dL in non-diabetic patients or in patients with type 2 diabetes using the drug alone.

That protection disappears when a GLP-1 agonist is combined with an insulin secretagogue. The 2024 Wegovy prescribing label states directly that hypoglycemia has been reported when semaglutide 2.4 mg is used with insulin or insulin secretagogues, and that the dose of those agents may need to be lowered to reduce the risk. The Zepbound (tirzepatide) 2024 label carries an identical warning. [1][2]

In STEP-2 (N=1,210 adults with type 2 diabetes), semaglutide 2.4 mg produced symptomatic hypoglycemia in approximately 6.2% of participants, nearly all of whom were also on a sulfonylurea or basal insulin at baseline. [3] In SURMOUNT-2 (N=938 adults with type 2 diabetes and obesity), tirzepatide 15 mg showed a similar pattern: hypoglycemia events were concentrated in patients already on background insulin or sulfonylurea therapy. [4]

Patients not on those companion drugs have very low rates. In STEP-1, which enrolled adults without diabetes, clinically significant hypoglycemia was not a notable adverse event in the semaglutide arm. [5]

Practical guidance: If you are prescribed a GLP-1 agonist while already taking glipizide, glimepiride, glyburide, or any basal or bolus insulin, ask your prescriber before your first injection whether your existing dose needs pre-emptive reduction. Carrying a 15-gram fast-acting carbohydrate snack is reasonable during the first 4 to 8 weeks of combination therapy.

The HealthRX clinical team uses a three-tier hypoglycemia risk stratification for GLP-1 starts:

Tier 1 (low risk): GLP-1 monotherapy in a patient without diabetes. No routine glucose monitoring required beyond standard metabolic panels.

Tier 2 (moderate risk): GLP-1 added to metformin alone. Metformin does not directly stimulate insulin secretion, so additive hypoglycemia risk is minimal. Routine monitoring still advised at 4-week and 12-week visits.

Tier 3 (higher risk): GLP-1 added to a sulfonylurea, meglitinide, or any insulin regimen. Proactive dose reduction of the secretagogue by 25 to 50% at GLP-1 initiation, with glucose log review at 2 weeks, is the standard HealthRX protocol.

GLP-1 Side Effects Overview: What the Trial Data Actually Show

The side-effect profile of GLP-1 receptor agonists is well-characterized across large randomized trials. Gastrointestinal symptoms dominate. In STEP-1 (N=1,961, Wilding et al. 2021, NEJM), participants on semaglutide 2.4 mg reported nausea in 44.2% of cases, diarrhea in 31.5%, vomiting in 24.8%, and constipation in 23.4%. Placebo rates for those same events were 16.1%, 15.9%, 6.8%, and 11.5%, respectively. [5] The drug arm showed roughly two to three times the GI event rate of placebo.

In SURMOUNT-1 (N=2,539, Jastreboff et al. 2022, NEJM), tirzepatide 15 mg produced nausea in 39%, diarrhea in 23%, constipation in 17%, and vomiting in 13% of participants. Discontinuation due to adverse events occurred in approximately 7% of those on 15 mg versus 3% on placebo. [6]

Serious adverse events are less frequent but clinically meaningful. Both drug classes carry a boxed warning for thyroid C-cell tumors based on rodent data, though a causal link in humans has not been established. Acute pancreatitis, gallbladder disease (including cholecystitis and cholelithiasis), and acute kidney injury secondary to dehydration during severe vomiting episodes are recognized risks documented in both FDA labels. [1][2]

The AACE 2016 obesity clinical practice guidelines note that GI tolerability is one of the primary factors affecting long-term adherence to pharmacotherapy, making proactive side-effect counseling a standard part of initiating these agents. [7]

Most GI events are mild to moderate in severity. A 104-week analysis from STEP-5 (N=304) confirmed that nausea rates dropped substantially after week 20 and did not re-emerge during continued use, suggesting the body adapts over time rather than experiencing persistent symptoms. [8]

How to Manage Nausea on Semaglutide or Tirzepatide

Nausea is the most common reason patients call their clinic during the first 12 weeks of GLP-1 therapy. It is driven primarily by slowed gastric emptying, the same mechanism that contributes to weight loss. The drug reduces the rate at which the stomach contracts and moves food into the small intestine; food sitting in the stomach longer triggers the nausea reflex.

Dietary adjustments that reduce nausea:

• Eat smaller portions. A meal volume of roughly half your prior portion size, consumed three to five times per day rather than two to three large meals, reduces gastric distension.
• Slow your eating pace to at least 20 minutes per meal. Rapid ingestion stresses an already slower-emptying stomach.
• Avoid high-fat meals on injection day and the following 24 hours. Fat delays gastric emptying further, compounding drug-induced slowing.
• Avoid carbonated beverages and alcohol during dose-escalation weeks. Both increase gastric pressure.
• Keep the head of your bed elevated 30 degrees if nausea is worst at night.

Medications for breakthrough nausea:

Ondansetron (Zofran) 4 mg orally as needed is widely used off-label for GLP-1-induced nausea. No large RCT has tested it specifically in this population, but its mechanism (5-HT3 antagonism) addresses one of the primary signaling pathways that GLP-1 agonists activate in the gut. Promethazine 12.5 to 25 mg at bedtime is a reasonable alternative for patients with nighttime-predominant symptoms, though sedation limits daytime use.

In STEP-8 (N=338, Rubino et al. 2022, JAMA), which compared semaglutide 2.4 mg directly to liraglutide 3.0 mg, nausea was reported in 49.9% of the semaglutide arm. That trial did not find that antiemetic co-prescription materially changed completion rates, but it confirmed that the majority of events were mild and resolved without medication changes. [9]

Do not automatically skip or delay your next injection because of nausea. Irregular dosing does not reliably reduce GI symptoms and disrupts the dose-escalation schedule designed to build tolerance. If nausea is severe enough to cause two or more episodes of vomiting per week, contact your prescriber. Holding at the current dose level for an extra 4 weeks is a recognized strategy in the Wegovy titration guidance. [1]

Managing Constipation on GLP-1 Therapy

Constipation affects roughly one in four patients on semaglutide and about one in six on tirzepatide, based on STEP-1 and SURMOUNT-1 data. [5][6] Slowed colonic transit is the underlying driver, again stemming from the drug's effect on gut motility. Unlike nausea, constipation tends to persist longer and does not fully resolve in the first 8 to 12 weeks for many patients.

First-line management steps:

1. Increase daily water intake to at least 2.5 liters. Dehydration from reduced appetite concentrates stool and worsens transit.
2. Add a soluble fiber supplement such as psyllium husk (Metamucil) 1 teaspoon once daily, taken with a full glass of water. Start low; increasing fiber too quickly adds bloating.
3. Move your body. Even 20 to 30 minutes of walking per day accelerates colon transit measurably.

Over-the-counter options:

Polyethylene glycol (MiraLAX) 17 g daily is well-tolerated and non-habit-forming. It works by drawing water into the colon rather than stimulating muscle contractions, which makes it appropriate for regular use during active GLP-1 titration. Stimulant laxatives such as senna should be reserved for acute episodes rather than daily use, given potential effects on colonic nerve function with prolonged exposure.

Do not use magnesium supplements casually without checking with your prescriber. High-dose magnesium can affect cardiac conduction, and patients already experiencing nausea may absorb magnesium unpredictably.

Severe constipation with abdominal distension, absence of bowel movements for more than 5 days, or significant pain warrants prompt medical evaluation. Ileus and obstruction, while rare, have been reported in the post-marketing period for GLP-1 agonists. The 2024 Zepbound label includes ileus among adverse reactions identified post-approval. [2]

What Causes Sulfur Burps on GLP-1 Medications and How to Reduce Them

Sulfur burps, the rotten-egg-smelling eructations that patients describe on forums and in clinic visits, are not a sign of drug toxicity. They reflect what happens when food, particularly sulfur-containing protein, ferments in a stomach that is emptying slowly. Bacteria in the upper GI tract produce hydrogen sulfide gas as a byproduct of that fermentation. The gas escapes upward as a sulfur-scented burp.

Foods highest in sulfur content that commonly trigger the symptom include eggs, red meat, cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), onions, garlic, and dairy protein. Patients often report that sulfur burps worsen in the 24 to 48 hours after injection, when gastric-emptying delay is at its peak.

Practical reduction strategies:

• Rotate away from high-sulfur foods during dose-escalation weeks. You do not need to eliminate them permanently, only during the weeks of maximum gastric slowing.
• Eat smaller meals and chew thoroughly. Larger food particles ferment faster.
• Bismuth subsalicylate (Pepto-Bismol) 262 to 524 mg after meals can bind hydrogen sulfide in the gut. It is not a long-term solution, but it provides real relief for acute episodes.
• Simethicone 80 to 125 mg after meals addresses excess gas pressure but does not neutralize the sulfur odor specifically. It may still reduce the frequency of burping.
• Activated charcoal supplements are sometimes used, but evidence in this specific context is anecdotal. Activated charcoal can also bind medications if taken too close to drug administration times, so any use should be timed at least 2 hours away from other drugs.

Sulfur burps typically improve as the body adjusts to the drug's gastric-emptying effect, usually within 8 to 16 weeks in most patients who stay on the medication. If they persist beyond 16 weeks at a maintenance dose, a gastroenterology referral to assess for Helicobacter pylori infection or small intestinal bacterial overgrowth (SIBO) may be warranted. Both conditions amplify upper GI fermentation independently of GLP-1 use.

When to Stop the Medication and Call Your Doctor

Most GLP-1 side effects are manageable. A small subset of presentations require immediate medical contact.

Call your prescriber within 24 hours if you experience:

• Persistent vomiting preventing oral hydration for more than 24 hours
• No bowel movement for 5 or more days, especially with abdominal pain
• Blood glucose readings below 70 mg/dL confirmed by meter (in patients also on insulin or sulfonylurea)
• Signs of dehydration: dark urine, dizziness on standing, heart rate above 100 at rest

Go to an emergency department immediately if you experience:

• Severe, persistent mid-abdominal pain that radiates to the back. This pattern is the classic presentation of acute pancreatitis and requires immediate evaluation with lipase testing.
• Right-upper-quadrant pain with fever. Acute cholecystitis is listed in both FDA labels as a post-marketing finding requiring urgent workup.
• Difficulty swallowing or severe heartburn that does not respond to antacids. While rare, cases of esophageal dysmotility have been reported.

A 2023 observational analysis published in JAMA (corresponding with SELECT trial data, N=17,604) found that cardiovascular benefit from semaglutide 2.4 mg was a 20% relative risk reduction in major adverse cardiovascular events versus placebo, a significant benefit for the majority of patients. [10] The point is that the risk-benefit calculation for most patients favors staying on therapy through GI side effects rather than discontinuing.

How Dose Titration Reduces Side-Effect Severity

The escalation schedule built into both Wegovy and Zepbound prescribing information exists specifically to reduce GI side-effect burden. Patients who skip ahead to higher doses prematurely experience meaningfully worse nausea and vomiting rates.

For semaglutide 2.4 mg (Wegovy), the standard schedule moves from 0.25 mg weekly for 4 weeks, to 0.5 mg for 4 weeks, to 1.0 mg for 4 weeks, to 1.7 mg for 4 weeks, then to the maintenance dose of 2.4 mg. [1] Each step gives the gut time to adapt to increased GLP-1 receptor activation.

For tirzepatide (Zepbound), the schedule begins at 2.5 mg weekly for 4 weeks, then escalates in 2.5 mg increments every 4 weeks to a maximum of 15 mg. [2]

STEP-3 (N=611, Wadden et al. 2021, JAMA) showed that adding intensive behavioral therapy to semaglutide 2.4 mg produced 16.0% mean weight loss at 68 weeks versus 13.9% with drug alone, but importantly the behavioral intervention group also reported better GI tolerability scores, likely because the dietary coaching reinforced smaller meals and high-fat food avoidance. [11]

If a patient cannot tolerate an escalation step, staying at the prior dose level for an additional 4 weeks is acceptable. This is explicitly noted in the Wegovy label as a dosing modification for tolerability. [1] Skipping doses is not an endorsed strategy; it introduces irregular drug exposure without meaningfully reducing total side-effect burden.

Drug Interactions That Change the Side-Effect Equation

Two interaction categories change the clinical picture meaningfully.

Oral contraceptives and other time-sensitive oral medications. Because GLP-1 agonists slow gastric emptying, peak absorption of oral drugs taken around injection time may shift. The FDA-approved label for both semaglutide and tirzepatide recommends that patients on oral contraceptives or levothyroxine take those medications at a consistent time each day and consider taking them on an empty stomach, separate from meals that coincide with maximum gastric slowing. [1][2] Patients on levothyroxine should have TSH rechecked at their standard 6-week interval after GLP-1 initiation.

Oral semaglutide (Rybelsus) and the absorption window. This interaction is unique to the oral formulation. Rybelsus must be taken on an empty stomach with no more than 4 oz of water and no food for 30 minutes afterward because the absorption window for the oral drug is narrow. Co-administration of any other oral medication within that window reduces bioavailability of the semaglutide itself.

Alcohol warrants a specific mention. Alcohol is a gastric irritant that compounds nausea when gastric emptying is already delayed. Patients who continue regular alcohol use during GLP-1 titration report higher nausea scores. Beyond nausea, alcohol causes hypoglycemia through gluconeogenesis inhibition, a risk that becomes additive if the patient is also on a background sulfonylurea or insulin.